๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Clinical trial register · China

Extensive-stage Small Cell Lung Cancer (ES-SCLC) Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Changsha 3 Shanghai 3 Beijing 3 Chengdu 3 Hangzhou 3
Narrow the registerReset
Recruitment status
Phase
Site location
Changsha3 Shanghai3 Beijing3 Chengdu3 Hangzhou3
All 16 locations
Target enrolment
to

Extensive-stage Small Cell Lung Cancer (ES-SCLC) trials in China

13 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Metronomic Oral Paclitaxel Plus PD-1/ PD-L1 Inhibitor Maintenance in Advanced Lung Cancer (PULSE Study)
NCT07744698Squamous Non-Small Cell Lung Cancer sqNSCLC, Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Anhui Provincial Cancer Hospital
Phase 4
107
Hefei
2026-07-24
Recruiting
DAREON ยฎ -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
NCT07472517Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Boehringer Ingelheim
Phase 3
670
Beijing, Bengbu, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2026-04-13
Not yet open
Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
NCT07501169Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Sichuan University
Phase 2
33
Sichuan
2026-04-01
Recruiting
A Study of Ivonescimab in First-Line ES-SCLC
NCT07245446Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Akeso
Phase 2
180
Beijing, Xi'an, Shanghai
2025-10-29
Recruiting
Tislelizumab Combined With Chemotherapy Followed by Thoracic Consolidation Radiotherapy in the First-line Treatment of Extensive Stage Small Cell Lung Cancer
NCT07425795Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Chongqing University Cancer Hospital
Phase 2
36
Chongqing
2025-10-10
Recruiting
Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
NCT07061535Extensive-stage Small Cell Lung Cancer (ES-SCLC), Extensive Stage Lung Small Cell Cancer, Extensive-Stage Small-Cell Lung Cancer, Extensive Disease Small Cell Lung Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
40
Changsha, Jinan, Hangzhou
2025-07-30
Not yet open
Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment for First-line Extensive-stage Small Cell Lung Cancer in the Cachexia Phase
NCT06961201Extensive-stage Small Cell Lung Cancer (ES-SCLC), The Pre-cachexia or Cachexia Patients Who Have Not Received Systemic Treatment and Are Not Eligible for Curative Therapy
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 3
94
Chengdu
2025-05-01
Recruiting
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
NCT06801834Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Gilead Sciences
Phase 3
695
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin
2025-04-04
Recruiting
Second-line Immunotherapy for ES-SCLC
NCT06853678Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Tianjin Medical University Cancer Institute and Hospital
Not applicable
30
Tianjin
2025-02-28
Recruiting
Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC
NCT06838208Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Anhui Provincial Cancer Hospital
Phase 2
56
Hefei
2025-02-25
Recruiting
Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer
NCT06758700Extensive-stage Small Cell Lung Cancer (ES-SCLC), Thoracic Neoplasms, Lung Neoplasms, Lung Diseases
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
15
Shanghai
2025-02-07
Active, closed
Real-world First-line Serplulimab-based Immunochemotherapy for Extensive-stage Small Cell Lung Cancer
NCT06748495Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Hunan Cancer Hospital
Observational
600
Changsha
2024-02-05
Recruiting
Small Extracellular Vesicle miRNAs as Predictive Biomarkers for Immunochemotherapy Efficacy in Extensive-stage Small Cell Lung Cancer
NCT07070011Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Shanghai Chest Hospital of Shanghai Jiao Tong University
Observational
38
Shanghai
2023-01-03
Rows per page Showing 1–13 of 13
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-china/condition/extensive-stage-small-cell-lung-cancer-es-sclc

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 13 of those studies listing the condition Extensive-stage Small Cell Lung Cancer (ES-SCLC).

How many Extensive-stage Small Cell Lung Cancer (ES-SCLC) trials are recruiting in China?

10 of the 13 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 2 have not yet opened recruitment, 1 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Extensive-stage Small Cell Lung Cancer (ES-SCLC)), 13 studies
PhaseStudiesRecruitingShare
Phase 26546.2%
Phase 33223.1%
Observational2115.4%
Not applicable117.7%
Phase 4117.7%

Most active sponsors

Lead sponsors with the most studies (Extensive-stage Small Cell Lung Cancer (ES-SCLC))
Lead sponsorStudiesRecruiting
Anhui Provincial Cancer Hospital22
Akeso11
Boehringer Ingelheim11
Changchun GeneScience Pharmaceutical Co., Ltd.10
Chongqing University Cancer Hospital11
Gilead Sciences11
Hunan Cancer Hospital10
Second Affiliated Hospital, Zhejiang University, School of Medicine11
Shanghai Chest Hospital of Shanghai Jiao Tong University11
Shanghai Pulmonary Hospital, Shanghai, China11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.